New Uganda Bill threatens progress on HIV/AIDS; impedes effective HIV response, violates rights

9 November 2009

A proposed Ugandan law on HIV/AIDS promotes dangerous and discredited approaches to the AIDS epidemic and would violate human rights, a group of more than 50 Ugandan and international organizations and individuals said in a report released November 6. The HIV and AIDS Prevention and Control Bill could be taken up by Uganda's parliament shortly.

The report, a 10-page analysis of the bill, was released in Kampala, Uganda, and Geneva, Switzerland, at a meeting on HIV treatment sponsored by the World Health Organization. The report criticizes repressive provisions in the legislation as contrary to the goal of universal access to HIV prevention, care, and treatment. The proposed law includes mandatory testing for HIV and forced disclosure of HIV status. It also criminalizes the wilful transmission of HIV, the failure to 'observe instructions on prevention and treatment,' and misleading statements on preventing or controlling HIV.

'We know what works and what doesn't in fighting HIV,' said Beatrice Were of the Uganda Network on Law, Ethics & HIV/AIDS. 'This Bill, unfortunately, is full of ineffective approaches that violate human rights and will set us back in our efforts to fight the AIDS epidemic and expand HIV programs nationwide,' she noted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical